Zaynich Is Here: What NPs Need to Know About the FDA's Newest Antibiotic for Complicated UTI
PHARMACOLOGY UPDATE | ANTIMICROBIAL THERAPY June 2026 | NP Chronicles Clinical Education Zaynich Is Here: What NPs Need to Know About the FDA's Newest Antibiotic for Complicated UTI By Valerie Watters-Burke, DNSc, MSN, MBA, FNP-BC, GNP-BC, PPCNP-BC CLINICAL BOTTOM LINE Cefepime-zidebactam (Zaynich) received FDA approval in June 2026 for complicated UTI (cUTI) and acute pyelonephritis (AP) caused by susceptible gram-negative pathogens, including drug-resistant strains. In the pivotal Phase 3 trial, it outperformed meropenem at the primary endpoint (89% vs. 68.4%) — a clinically meaningful difference that NPs treating hospitalized patients with resistant infections need to know. Why This Approval Matters Antimicrobial resistance is one of the defining clinical challenges of our era. For NPs working in hospital-based, telehealth urgent care, or primary care settings, complicated urinary tract infections — espe...